PAs and Migration of VSMCs
Neointimal migration of VSMCs depends on surface expression of PAs. 6, [22] [23] [24] Plasmin generated from plasminogen in the extracellular matrix activates MMPs and facilitates migration. Thus, proteolysis is pivotal in initiation of plaque formation (activation of monocytes/macrophages), migration of VSMCs (surface proteo[fibrino]lysis), and rupture of complex plaques precipitating ACS.
This paradigm accounts for the precipitous decrease in incidence of ACS (by 25% to 80%) after lipid lowering despite only trivial diminution of obstruction (0.054% to 2.2%). 25, 26 The dichotomy reflects plaques being rendered more stable by reduction of the ratio of core lipid to cellular elements. 27 The paradigm accounts also for decreased ACS seen with the use of anti-inflammatory, antiplatelet, and anticoagulant agents. 28, 29 
Resolution of the Paradox
One condition underlying ACS, 30 insulin resistance with or without impaired glucose tolerance or frank type 2 diabetes mellitus, is characterized by inhibition of proteolysis. 10, 31, 32 Thus, PAI-1 is increased in blood 32 and in coronary plaques in patients with type 2 diabetes. 10 Insulin increases PAI-1 protein and mRNA in vessel walls and PAI-1 protein in blood. 33, 34 Hyperinsulinemia induced in normal subjects increases blood PAI-1. 35 Although it is obvious that increased PAI-1 can limit fibrinolysis and potentiate thrombosis that precipitates ACS, it is not obvious how increased PAI-1 and decreased proteo(fibrino)lysis in vessel walls can exacerbate vasculopathy, because proteolysis is so pivotal in atherogenesis. Furthermore, plasminogen knockout mice 36 exhibit decreased migration of VSMCs after electrical injury to vessels that has been interpreted as indicative of protection against vasculopathy. In addition, in PAI-1-overproducing mice, VSMC migration is attenuated, 37 and VSMC accumulation is reduced at sites of injury. 35 The conventional wisdom holds that (1) accumulation of VSMCs and formation of a thick, cellular neointima is "bad" (a hallmark of "malignant" atherosclerotic lesions), and (2) inhibition of migration of VSMCs (and subsequent proliferation) is "good." However, this view may be wrong.
In evolving atheroma, elevation of PAI-1 is marked. 10 PAI-1 is prominent in early fatty lesions in nondiabetic subjects 38 and in complex atheroma known to predispose to ACS in diabetic subjects. 10 As in PAI-1-overproducing mice, 37 the increased PAI-1 should inhibit VSMC migration, subsequent proliferation, and accumulation. However, such inhibition may be bad if it predisposes to formation of acellular plaques. By analogy, inhibition of scar formation makes wound healing "look better" but predisposes to dehiscence; inhibition of granuloma formation with mycobacterial
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From the Department of Medicine, The University of Vermont Collegeinfection makes the lung "look better" but predisposes to death. Thus, inhibition of VSMC migration may make evolving atheroma look better yet predispose to formation of preponderantly acellular plaques particularly prone to rupture.
In fact, observations in genetically modified mice 36, 37 are consistent with this interpretation. The response to injury is impaired migration of VSMCs and a disproportionate decrease in the ratio of VSMCs to matrix and fibrous tissue. These findings may in fact reflect an impaired response to injury that sets the stage for the thin-walled aneurysms seen rather than protection against vasculopathy. Observations in patients with hyperinsulinemia and type 2 diabetes are consistent with this view. 10 The increased level of PAI-1 in atheroma and in vessel walls appears likely to potentiate formation of atheroma plaques with lipid-laden cores and thin fibrous caps-plaques particularly prone to rupture. This would account for the high incidence of ACS and the adverse response to angioplasty (4-fold increase in 5-year mortality to 35%). 39 Construing inhibition of migration of VSMCs as deleterious and migration as protective requires a novel perspective. Changing one's mind-set is analogous, in a sense, to shifting from 1 perceived element to another in an Esher drawing (Figure) .
Clinical Implications
If the proposed views are correct, inhibition of augmented vessel-wall PAI-1 expression should lead to favorable changes in composition of atherosclerotic plaques that evolve. Increased degradation and decreased accumulation of matrix and robust migration of VSMCs into developing lesions can be anticipated. Thus, a decreased ratio of lipid to VSMCs that renders plaques less prone to rupture would be expected. Similarly, reduced PAI-1 in vessel walls should decrease the incidence of ACS. We have found that thiazolidinediones (insulin sensitizers) decrease PAI-1 in blood in hyperinsulinemic subjects. 40 Favorable changes in carotid intimal-medial thickness consistent with reduction of lipid content have been observed as well in a preliminary study. 41 Atherogenesis is multifactorial. Increased PAI-1 is certainly not its proximate cause. However, increased PAI-1 may predispose to formation of plaques with high lipid-to-VSMC ratios as a result of decreased VSMC migration. Such plaques are particularly prone to rupture and to precipitate ACS. Thus, suppression of PAI-1 gene expression is an attractive pharmacological target.
